Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

Novavax signs licensing agreement with Pfizer for vaccine development

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

The near death — and last-minute reprieve — of a trial for an HIV vaccine

A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...

Review finds that future vaccine trials must include care home residents

The first review of vaccine trials conducted in care homes concludes that it is "crucial" that future vaccine trials include ...

Study suggests vaccine trials should include care homes

The University of Aberdeen-led review looked at thousands of cases across the United Kingdom.
Contract Pharma

SK Bioscience to Support CEPI-Backed Development of Updated Zaire Ebolavirus Vaccine

SK Bioscience has joined a new international effort to advance an updated Zaire ebolavirus vaccine, following a funding agreement between the CEPI and Merck & Co.
Fierce Pharma

CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others

With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. | The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT ...